Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 02.11.2026 1 ACS Nano 2 Ann Surg Oncol 3 Anticancer Res 1 Antioxidants (Basel) 1 Asian Pac J Cancer Prev 1 Biochem Biophys Res Commun 1 Biol Direct 1 BMC Cancer 1 BMC Med Genomics 1 BMC Med Imaging 1 BMJ Open 1 Bull Cancer 1 Cancer Immunol Res 2 Cancer Radiother 2 Cancers (Basel) 1 Cell Death Differ 1 Cell Signal 1 Chem Biomed Imaging 1 Clin Genitourin Cancer 1 Clin Transl Radiat Oncol 2 Crit Rev Oncol Hematol 2 Curr Issues Mol Biol 1 Curr Oncol 3 Curr Urol 2 Eur Urol Focus 1 Front Genet 1 Front Oncol 1 Funct Integr Genomics 1 Future Oncol 2 In Vivo 1 Indian J Pathol Microbiol 1 Int J Med Robot 4 Int J Mol Sci 1 Int J Urol 1 J Cancer Res Clin Oncol 1 J Endourol 1 J Environ Pathol Toxicol Oncol 2 J Immunother Cancer 1 J Med Imaging Radiat Oncol 1 J Nanobiotechnology 1 J Natl Compr Canc Netw 1 J Robot Surg 1 J Urol 1 JAMA Oncol 3 Lancet Oncol 2 Medicina (Kaunas) 1 N Engl J Med 1 Nat Med 1 Nat Rev Urol 1 PLoS One 1 Rev Col Bras Cir 1 Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 1 Urol Oncol 1 Urol Pract 1 Urologia 2 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

ACS Nano

1. YU P, Gao M, Feng X, Rong H, et al
   Gold Nanourchins Potentiate Intravesical Chemotherapy by Accelerating Drug Internalization within a Short Instillation Window.
   ACS Nano. 2026;20:28442-28456.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. ZHAO Y, Zhang S, Chen J
   ASO Author Reflections: From the Bedside to the Culture Dish: How Bladder Cancer Organoids Illuminate the Path Toward Precision Chemotherapy.
   Ann Surg Oncol. 2026 Oct 26. doi: 10.1245/s10434-026-20820.
   PubMed        
   
   
3. ZHAO Y, Zhang S, Wang Y, Shen Z, et al
   Patient-Derived Organoids for Predicting Chemotherapy Response in Bladder Cancer: A Multicenter, Real-world Validation Study.
   Ann Surg Oncol. 2026 Oct 26. doi: 10.1245/s10434-026-20781.
   PubMed         Abstract available
   
   

   
   Anticancer Res

4. SHIMIZU T, Nagano Y, Morioka Y, Miyashita M, et al
   TIM-3 Up-regulation Is Associated With Altered Cytotoxic Function of Allogeneic Vgamma9Vdelta2 T Cells in Urinary Bladder Cancer.
   Anticancer Res. 2026;46:6017-6027.
   PubMed         Abstract available
   
   
5. SANO A, Tamura K, Sakai Y, Kahyo T, et al
   High Ubiquitin-like Protein 3 Expression Is Associated With Prolonged Recurrence-free Survival in Non-muscle-invasive Bladder Cancer.
   Anticancer Res. 2026;46:6249-6263.
   PubMed         Abstract available
   
   
6. CHEN HW, Li JR, Wang SS, Yang CK, et al
   Overall Survival After Neoadjuvant Versus Adjuvant Chemotherapy for Invasive Urothelial Carcinoma of the Bladder: A Real-world Multicenter Cohort Study.
   Anticancer Res. 2026;46:6331-6341.
   PubMed         Abstract available
   
   

   
   Antioxidants (Basel)

7. TAYLOR JA 3RD, Parikh RA, Chen Q, Woolbright BL, et al
   IV Vitamin C with Chemotherapy for Cisplatin-Ineligible Bladder Cancer Patients: A Forgotten Group.
   Antioxidants (Basel). 2026;15:1318.
   PubMed         Abstract available
   
   

   
   Asian Pac J Cancer Prev

8. SANGKHATHAT S, Kanjanapradit K, Bejrananda T, Choochuen P, et al
   Prognostic Value of PD-L1 and Its Correlation with GATA3, CK5/6, and CK14 Expression in Muscle-Invasive Bladder Cancer.
   Asian Pac J Cancer Prev. 2026;27:3645-3653.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

9. WANG H, Wang B, Liu H, Wu J, et al
   PCB-118 increases PDE4D abundance and thermal stability in bladder cancer cells: An integrative toxicogenomic and cellular study.
   Biochem Biophys Res Commun. 2026;841:154810.
   PubMed         Abstract available
   
   

   
   Biol Direct

10. LENG X, Lu W, Zhou R, Wang C, et al
    Targeting MRPL37 disrupts the pro-tumorigenic mitochondrial cascade in bladder cancer: from LRPPRC deficiency to ROS/AKT axis inhibition.
    Biol Direct. 2026;21:215.
    PubMed         Abstract available
    
    

    
    BMC Cancer

11. HAO WP, Lin ZB, Ke L, Liu HJ, et al
    Overexpression of small nucleolar RNA host gene family members predicts poor bladder cancer prognosis: based on a systematic review and meta-analysis.
    BMC Cancer. 2026;26:1324.
    PubMed         Abstract available
    
    

    
    BMC Med Genomics

12. XU M, Song X, Kudusi, Zu X, et al
    SLCO1B3 is associated with poor survival and promotes bladder cancer progression through Wnt/beta-catenin signaling.
    BMC Med Genomics. 2026;19:165.
    PubMed         Abstract available
    
    

    
    BMC Med Imaging

13. HE P, Chen R, Zheng Q, Tian M, et al
    Development and validation of a preoperative biparametric MRI-based habitat model for risk stratification of non-muscle-invasive bladder cancer.
    BMC Med Imaging. 2026;26:563.
    PubMed         Abstract available
    
    

    
    BMJ Open

14. LEE HW, Park YH, Kim KH, Jung EH, et al
    Sequential intravesical mitomycin-C and gemcitabine therapy for BCG-unresponsive high-risk non-muscle-invasive bladder cancer: protocol for a prospective, open-label, single-arm, multicentre phase II (IMGeS) study.
    BMJ Open. 2026;16:e117239.
    PubMed        
    
    

    
    Bull Cancer

15. ANDRE C, Tournier L, Fardeau E, Fiore A, et al
    Type A acute aortic dissection associated with 5-fluorouracil: A rare but serious vascular toxicity.
    Bull Cancer. 2026;113:1303-1305.
    PubMed         Abstract available
    
    

    
    Cancer Immunol Res

16. GHASEMZADEH A, Pietzak EJ
    Tertiary Lymphoid Structures in Non-Muscle-Invasive Bladder Cancer: Quality over Quantity.
    Cancer Immunol Res. 2026 Oct 27:OF1-OF2. doi: 10.1158/2326-6066.CIR-26-1127.
    PubMed         Abstract available
    
    

    
    Cancer Radiother

17. HUCK C, Zobouyan C, Pignot G, Marcq G, et al
    Postoperative radiotherapy after radical cystectomy for muscle-invasive bladder cancer: Patient selection, target delineation and contemporary evidence.
    Cancer Radiother. 2026;30.
    PubMed         Abstract available
    
    
18. HUCK C, Pignot G, Masson-Lecomte A, Pasquier D, et al
    Quality of life after trimodal treatment for muscle-invasive bladder cancer.
    Cancer Radiother. 2026;30.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

19. GHERASIM RD, Porav-Hodade D, Chibelean C, Voidazan S, et al
    Development and Internal Validation of the BRICS Score: A Preoperative Clinical and Hematological Model for Predicting High-Grade and Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2026;18:3282.
    PubMed         Abstract available
    
    
20. DENG H, Sun R, He G, Tan Y, et al
    The SP4-NUPR1-SELM Axis Promotes Glycolytic Reprogramming and Stemness-Associated Phenotypes in Bladder Cancer.
    Cancers (Basel). 2026;18:3396.
    PubMed         Abstract available
    
    

    
    Cell Death Differ

21. CAO C, Lai Y, Ye W, Wang Z, et al
    DCST1 drives cisplatin resistance via non-canonical ubiquitination and stabilization of NFAT5 to suppress PANoptosis in bladder cancer.
    Cell Death Differ. 2026 Oct 28. doi: 10.1038/s41418-026-01866.
    PubMed         Abstract available
    
    

    
    Cell Signal

22. JIN X, Xu Y, Ling K, Li H, et al
    Elevated GANAB fuels PD-1/PD-L1 checkpoint-mediated immune escape by maintaining PD-L1 stability in bladder cancer.
    Cell Signal. 2026;150:112937.
    PubMed         Abstract available
    
    

    
    Chem Biomed Imaging

23. TONG P, Tu J, Li M, Peng X, et al
    Catheter-Integrated Nanosensors Unmask Bladder Cancer.
    Chem Biomed Imaging. 2026;4:2126-2128.
    PubMed        
    
    

    
    Clin Genitourin Cancer

24. RITTER J, Barker K, Marco T, Rao A, et al
    The Effect of Socioeconomic Inequality as Measured by a Standardized Neighborhood Deprivation Index on the Tumor Microenvironment and Genomics of Bladder Cancer.
    Clin Genitourin Cancer. 2026 Sep 20:102681. doi: 10.1016/j.clgc.2026.102681.
    PubMed         Abstract available
    
    

    
    Clin Transl Radiat Oncol

25. WILLIAMS B, Sandoughdaran S, Chick J, Dunlop A, et al
    Feasibility of reduced PTV margins in magnetic resonance image-guided online adaptive radiotherapy for bladder cancer: a personalised approach.
    Clin Transl Radiat Oncol. 2026;62:101321.
    PubMed         Abstract available
    
    

    
    Crit Rev Oncol Hematol

26. YAJIMA S, Okumura G, Yoshida S, Chen W, et al
    Time-varying prognostic value of circulating tumor DNA in urothelial carcinoma: A systematic review and reconstructed patient-data meta-analysis.
    Crit Rev Oncol Hematol. 2026;227:105560.
    PubMed         Abstract available
    
    
27. ZHANG T, Zhang H
    Urinary biomarkers for cancer diagnosis and surveillance: From analytical promise to clinical utility.
    Crit Rev Oncol Hematol. 2026;227:105519.
    PubMed         Abstract available
    
    

    
    Curr Issues Mol Biol

28. CHANG HH, Teng PC, Liu CH, Lin YL, et al
    A Programmed Cell Death Protein 1 Pathway-Derived Prognostic Transcriptomic Signature in Bladder Cancer: Development in TCGA-BLCA and Evaluation in Independent Cohorts.
    Curr Issues Mol Biol. 2026;48:1056.
    PubMed         Abstract available
    
    
29. ZHANG X, Taoka R, Liu D, Hossain A, et al
    Targeting Glucose Metabolism in Bladder Cancer: Therapeutic Implications of 2-Deoxy-d-glucose.
    Curr Issues Mol Biol. 2026;48:993.
    PubMed         Abstract available
    
    

    
    Curr Oncol

30. SCAVUZZO A, Castillejos-Molina RA, Bravo-Castro I, Jimenez-Rios MA, et al
    Patient Journey and Treatment Patterns of Non-Muscle-Invasive Bladder Cancer in Mexico.
    Curr Oncol. 2026;33:597.
    PubMed         Abstract available
    
    

    
    Curr Urol

31. GU Y, He W, Yu X, Jiang C, et al
    The current landscape of bladder-sparing therapies in BCG-refractory high-risk nonmuscle-invasive bladder cancer.
    Curr Urol. 2026;20:359-367.
    PubMed         Abstract available
    
    
32. DIAMANTIDIS D, Tsakaldimis G, Smyrlis N, Chousein C, et al
    Explainable artificial intelligence in prostate and bladder cancer: A review of imaging, digital pathology, molecular profiling, and clinical data.
    Curr Urol. 2026;20:332-348.
    PubMed         Abstract available
    
    
33. PEI G, Liang Y, Zhang W, Kang M, et al
    Application of rapidly prepared nonactivated high-efficiency chimeric antigen receptor T cells in the treatment of bladder cancer.
    Curr Urol. 2026;20:379-391.
    PubMed         Abstract available
    
    

    
    Eur Urol Focus

34. DANESHMAND S, Wuyts K, Meulder M, Vereyken L, et al
    Tissue Penetration of Gemcitabine and Gemcitabine Phosphate Metabolites Following Gemcitabine Intravesical System Administration Versus Standard Intravesical Instillation in a Preclinical Minipig Model.
    Eur Urol Focus. 2026;12:888-892.
    PubMed         Abstract available
    
    
35. VAN GENNEP EJ, Claps F, KleinJan GH, Bostrom PJ, et al
    The Prognostic Value of Lymphovascular Invasion in Combination with Nodal Stage on Disease-specific Survival in Patients with Bladder Cancer Following Upfront Radical Cystectomy.
    Eur Urol Focus. 2026 Oct 28:S2405-4569(26)00200.
    PubMed         Abstract available
    
    

    
    Front Genet

36. XIN LL, Guo JJ, Zheng XY, Li ZY, et al
    Perioperative immunogenomics and clinical outcomes under ERAS-based nursing care in muscle-invasive bladder cancer.
    Front Genet. 2026;17:1967034.
    PubMed         Abstract available
    
    

    
    Front Oncol

37. LUO H, Xu C, Liu Y, Yao Y, et al
    Association of MAGEA4 expression with molecular and immune subtypes and clinical outcomes in recurrent bladder cancer.
    Front Oncol. 2026;16:1906141.
    PubMed         Abstract available
    
    

    
    Funct Integr Genomics

38. HU C, Wang F, Zhang Q, Xu H, et al
    Deep learning-based multiomics integration identifies AI-defined tissue regions associated with cancer-associated fibroblast enrichment and chemoresistance in muscle-invasive bladder cancer.
    Funct Integr Genomics. 2026;26:308.
    PubMed         Abstract available
    
    

    
    Future Oncol

39. ZEMANKOVA A, Melichar B, Eid M, Poprach A, et al
    Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma.
    Future Oncol. 2026;22:2709-2715.
    PubMed         Abstract available
    
    

    
    In Vivo

40. UENO S, Yasuda R, Fujita N, Tsukamoto Y, et al
    Anti-gicerin IgG Reduces Adhesion, Wound Closure and Post-seeding Tumor Burden in T24 Bladder Carcinoma Models.
    In Vivo. 2026;40:3351-3366.
    PubMed         Abstract available
    
    
41. TSUBOTA S, Kaneko GO, Igarashi D, Takahashi T, et al
    Initial Clinical Experience With Gemcitabine, Cisplatin, and Nivolumab for Advanced Urothelial Carcinoma: A Four-case Series.
    In Vivo. 2026;40:3912-3921.
    PubMed         Abstract available
    
    

    
    Indian J Pathol Microbiol

42. CHATURVEDI A, Nisam I, Mallya V, Mandal S, et al
    PD-L1 Expression in muscle-invasive bladder carcinoma: correlation with tumor-stroma ratio and clinicopathological parameters.
    Indian J Pathol Microbiol. 2026;69:425-429.
    PubMed         Abstract available
    
    

    
    Int J Med Robot

43. MORIYAMA S, Shinohara M, Ogawa K, Inui K, et al
    Single-Port Robot-Assisted Radical Cystectomy Using Combined Umbilical and Perineal Access: Initial Clinical Experience With Exploratory Comparison of Multiport Surgery.
    Int J Med Robot. 2026;22:e70240.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

44. DEMIRCILER E, Ozalp FR
    Opposing Natural Killer and Macrophage Associations Are Masked Within a CD16/IL-15/IL-15RA Composite Score in Metastatic Urothelial Carcinoma.
    Int J Mol Sci. 2026;27:8943.
    PubMed         Abstract available
    
    
45. CARAPITO A, Amaro F, Roque AC, Carvalho F, et al
    Urinary Metabolomics in Bladder Cancer: A Scoping Review of Current Evidence and Translation Implications.
    Int J Mol Sci. 2026;27:8983.
    PubMed         Abstract available
    
    
46. LIANG H, Li G, Zhang W, Wang W, et al
    pH-Responsive Erdafitinib Liposomes with FGFR3 Targeting for Intravesical Bladder Cancer Therapy.
    Int J Mol Sci. 2026;27:9014.
    PubMed         Abstract available
    
    
47. XIE F, Su M, Qiu W, Zhang M, et al
    Correction: Xie et al. Kaempferol Promotes Apoptosis in Human Bladder Cancer Cells by Inducing the Tumor Suppressor, PTEN. Int. J. Mol. Sci. 2013, 14, 21215-21226.
    Int J Mol Sci. 2026;27:8989.
    PubMed         Abstract available
    
    

    
    Int J Urol

48. KASAHARA R, Ueki T
    Interpreting International Real-World Survival Outcomes After Avelumab First-Line Maintenance in Advanced Urothelial Carcinoma: An RMST Analysis of Reconstructed Individual Patient Data.
    Int J Urol. 2026;33:e70678.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

49. HAIYA F, Qianqian L, Yangjun L, Hui W, et al
    Isorhamnetin inhibits bladder cancer progression by mediating glycolysis through targeting the SRC/PI3K/Akt axis.
    J Cancer Res Clin Oncol. 2026;152:203.
    PubMed         Abstract available
    
    

    
    J Endourol

50. WEI Y, Liu Q, Li S, Jia F, et al
    Combined Application of 3D Reconstruction and ICG Fluorescence Imaging in Pelvic Lymph Node Dissection for Bladder Cancer: A Retrospective Study.
    J Endourol. 2026 Oct 28:8927790261502136. doi: 10.1177/08927790261502136.
    PubMed         Abstract available
    
    

    
    J Environ Pathol Toxicol Oncol

51. ZHANG W, Zheng K, Peng M, Zhang J, et al
    Comprehensive Characterization of Crotonylation-Related Long Non-Coding RNAs Reveals a Prognostic Signature and Functional Landscape in Bladder Cancer.
    J Environ Pathol Toxicol Oncol. 2026;45:1-23.
    PubMed         Abstract available
    
    

    
    J Immunother Cancer

52. ZHUANG R, Wu Z, Zheng R, Chen Y, et al
    Intratumoral Klebsiella pneumoniae drives metabolic-immune remodeling and immunotherapy resistance in bladder cancer.
    J Immunother Cancer. 2026;14:e016574.
    PubMed        
    
    
53. YOU Y, Zhang H, Sun J, Shuai Y, et al
    Non-canonical function of SCIMP restricts JAK1 activity to counteract immune evasion in bladder cancer.
    J Immunother Cancer. 2026;14:e015651.
    PubMed        
    
    

    
    J Med Imaging Radiat Oncol

54. YU J, Fu Y
    MRI Radiomics Can Advance Phenotype-Based Characterization of Bladder Cancer Variants.
    J Med Imaging Radiat Oncol. 2026 Oct 27. doi: 10.1111/1754-9485.70215.
    PubMed        
    
    

    
    J Nanobiotechnology

55. WANG X, Jin L, Zhang Q, Li M, et al
    Novel nanotherapeutic strategy targeting mechanical tumor microenvironment in bladder cancer.
    J Nanobiotechnology. 2026;24:991.
    PubMed         Abstract available
    
    

    
    J Natl Compr Canc Netw

56. NUSBAUM DJ, Ferguson JE 3rd, Spiess PE, Li R, et al
    New and Emerging Options for the Treatment of Non-Muscle-Invasive Bladder Cancer.
    J Natl Compr Canc Netw. 2026 Oct 27:e267061. doi: 10.6004/jnccn.2026.7061.
    PubMed         Abstract available
    
    

    
    J Robot Surg

57. SASAKI Y, Fukuta K, Kadoriku F, Hori K, et al
    Real-world implementation of robot-assisted radical cystectomy at four Japanese institutions: perioperative outcomes, major complications, and mortality.
    J Robot Surg. 2026;20:1129.
    PubMed         Abstract available
    
    

    
    J Urol

58. STROUD M, Talwar R, Bjurlin MA
    The Missing Comparator: Smoking Cessation Cost-Effectiveness in the Era of Novel Bladder Cancer Therapies.
    J Urol. 2026 Oct 28:101097JU0000000000005359. doi: 10.1097/JU.0000000000005359.
    PubMed        
    
    

    
    JAMA Oncol

59. COLLINS K, Cheng L
    FGFR Alterations in Bladder Cancer-From Molecular Pathogenesis to Precision Oncology.
    JAMA Oncol. 2026 Oct 29. doi: 10.1001/jamaoncol.2026.4196.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

60. TYSON MD 2ND, Li R
    BCG-unresponsive non-muscle-invasive bladder cancer - Authors' reply.
    Lancet Oncol. 2026;27:e536.
    PubMed        
    
    
61. SUN M, Zang D, Chen J
    BCG-unresponsive non-muscle-invasive bladder cancer.
    Lancet Oncol. 2026;27:e535.
    PubMed        
    
    
62. SCILIPOTI P, Moschini M, Briganti A, Montorsi F, et al
    BCG-unresponsive non-muscle-invasive bladder cancer.
    Lancet Oncol. 2026;27:e534.
    PubMed        
    
    

    
    Medicina (Kaunas)

63. CAGLAYAN D, Goktas E, Somuncu MN, Kilinc F, et al
    FGFR 1-3 Alteration Frequency in Muscle-Invasive Urothelial Bladder Cancer and Its Effect on Prognosis.
    Medicina (Kaunas). 2026;62:2026.
    PubMed         Abstract available
    
    
64. SAYLAM B, Temelli B, Nebioglu A, Efesoy O, et al
    Early Dynamic (18)F-FDG PET/CT SUVmax and Its Association with Pathological Stage and Tumor Grade in Bladder Cancer: A Prospective Exploratory Study.
    Medicina (Kaunas). 2026;62:2021.
    PubMed         Abstract available
    
    

    
    N Engl J Med

65. POWLES T, Grande E, Simone G, Gomez de Liano A, et al
    Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer.
    N Engl J Med. 2026 Oct 24. doi: 10.1056/NEJMoa2608323.
    PubMed         Abstract available
    
    

    
    Nat Med

66. NECCHI A, Mercinelli C, Maiorano BA, Piacentini M, et al
    Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.
    Nat Med. 2026 Oct 24. doi: 10.1038/s41591-026-04740.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

67. MASONE MC
    Urine cfRNA liquid biopsy for bladder cancer.
    Nat Rev Urol. 2026 Oct 27. doi: 10.1038/s41585-026-01211.
    PubMed        
    
    

    
    PLoS One

68. TOBE T, Teishima J, Hara T, Shiraishi Y, et al
    Enhanced enfortumab vedotin sensitivity in a cisplatin-resistant bladder cancer model.
    PLoS One. 2026;21:e0361593.
    PubMed         Abstract available
    
    

    
    Rev Col Bras Cir

69. PETRY MA, Polakowski CB, Rabito EI, Kool R, et al
    Impact of the Multimodal Protocol on the Outcomes of Cancer Patients Undergoing Radical Cystectomy.
    Rev Col Bras Cir. 2026;53:e2026005826.
    PubMed         Abstract available
    
    

    
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi

70. ZHENG M, Gao X, Liu J, Tan L, et al
    [Efficacy evaluation of extracellular vesicle drug delivery system in orthotopic intravesical perfusion for bladder cancer].
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2026;43:1068-1074.
    PubMed         Abstract available
    
    

    
    Urol Oncol

71. ZHENG C, Ren X, Qian C, Lei Z, et al
    Multi-omics profiling of FFPE tissues identifies serine synthesis and impaired creatine metabolism as metabolic hallmarks of high-grade bladder cancer.
    Urol Oncol. 2026 Oct 24:S1078-1439(26)00749.
    PubMed         Abstract available
    
    

    
    Urol Pract

72. CONTIERI R, Sormani F, Soloway M, Brausi M, et al
    Rethinking Recurrent LG Ta Bladder Cancer: A Multicenter Analysis of Oncological Safety and Treatment Burden in Patients Undergoing Active Surveillance or Office-Based Fulguration.
    Urol Pract. 2026 Oct 27:101097UPJ0000000000001111.
    PubMed         Abstract available
    
    

    
    Urologia

73. OLA L, Busacca G, Dalmasso E, Giordano A, et al
    Real-world diagnostic performance of pre-TURBT multiparametric MRI using VI-RADS for detecting muscle-invasive bladder cancer: A retrospective single-center study.
    Urologia. 2026 Oct 29:3915603261499101. doi: 10.1177/03915603261499101.
    PubMed         Abstract available
    
    

    
    World J Urol

74. YUK HD, Han JH, Jeong SH, Jeong CW, et al
    Perioperative outcomes of intracorporeal versus extracorporeal urinary diversion following robot-assisted radical cystectomy in multicenter KORARC database.
    World J Urol. 2026;44:763.
    PubMed         Abstract available
    
    
75. OLA L, Busacca G, Dalmasso E, Ornaghi PI, et al
    Implementation of a same-session outpatient diode laser ablation pathway for suspected recurrent low-grade NMIBC: feasibility, safety, and early outcomes.
    World J Urol. 2026;44:772.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum